Sivifene

CAS No. 2675-35-6

Sivifene ( —— )

Catalog No. M28587 CAS No. 2675-35-6

Sivifene can be used for research on the treatment of cutaneous metastases from cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 Get Quote
10MG 60 Get Quote
25MG 88 Get Quote
50MG 129 Get Quote
100MG 178 Get Quote
500MG 467 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Sivifene
  • Note
    Research use only, not for human use.
  • Brief Description
    Sivifene can be used for research on the treatment of cutaneous metastases from cancer.
  • Description
    Sivifene can be used for research on the treatment of cutaneous metastases from cancer.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2675-35-6
  • Formula Weight
    394.3
  • Molecular Formula
    C19H14N4O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Oc1ccc(cc1)C(=NNc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O)c1ccc(O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Tian LW, et al. ApoE secretion modulating bromotyrosine derivative from the Australian marine sponge Callyspongia sp. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3537-40.
molnova catalog
related products
  • (4S)-4-Hydroxy-L-iso...

    4-Hydroxyisoleucine (HIL) from fenugreek (Trigonella foenum-graecum) seeds is a potential insulinotropic (anti-diabetic) and anti-obesity amino acid.

  • ATI-2341 TFA (133787...

    ATI-2341 is an effective functionally selective allosteric agonist for the c-x-c chemokine receptor type 4 (CXCR4), which ACTS as a biased ligand in favor of G G G G G 1 activation instead of G G G G G 13.ATI-2341 activates the inhibitory heterotrimer G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.ATI-2341 is an effective mobilization agent for myeloid polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).

  • Aficamten

    Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.